Purchase this article for $4.95

Publication: Business Wire
Publication Date: 07-DEC-05
Delivery: Immediate Online Access
Author:
Company: Teva Pharmaceutical Industries Ltd.

Article Excerpt
JERUSALEM, Israel -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Oxycodone Extended Release Tablets, 10 mg, 20 mg and 40 mg. Shipment will begin immediately.

Teva's Oxycodone ER Tablets are the AB-rated generic equivalent of Purdue Pharma's Oxycontin(R) Tablets, a product indicated for the treatment of moderate to severe pain when continuous analgesia is needed for an extended period of time.

Total annual...

NOTE: All illustrations and photos have been removed from this article.



More articles from Business Wire
Public Relations Blog, Online Publicity Journal, Announces Site Redesign with Additional Press Release Resources., 15-JAN-08
SYNNEX Corporation Sets Record and Meeting Dates for 2008 Annual Meeting of Stockholders., 11-JAN-08
Arrow Electronics to Acquire Components Distribution Business of Hynetic Electronics and Shreyanics Electronics in India., 11-JAN-08

Looking for additional articles?
Click here to search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Click here to search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.